| Literature DB >> 27942875 |
Amer Saeed Alshahrani1, Ghung-Sik Gong1, Moon-Won Yoo2.
Abstract
BACKGROUND: Several studies have suggested no difference in the liver function of early gastric cancer (EGC) patients with liver cirrhosis (LC) between laparoscopic and open distal gastrectomy. However, the number of patients and comparison of long-term survival rates between the two groups are limited. The purpose of this study was to compare the long-term survival and immediate postoperative liver function of EGC patients with LC after laparoscopic and open distal gastrectomy.Entities:
Keywords: Gastric cancer; Laparoscopic gastrectomy; Liver cirrhosis; Survival
Mesh:
Year: 2016 PMID: 27942875 PMCID: PMC5486494 DOI: 10.1007/s10120-016-0675-4
Source DB: PubMed Journal: Gastric Cancer ISSN: 1436-3291 Impact factor: 7.370
Patient demographics
| Total no. = 75 | OG (48) | LG (27) |
|
|---|---|---|---|
| Age (years, mean ± SD) | 58.4 ± 9.6 | 59.6 ± 9.7 | 0.607 |
| Sex (male/female) | 43/5 | 23/4 | 0.714 |
| Underlying disease | |||
| DM | 14 | 3 | 0.090 |
| HTN | 13 | 11 | 0.303 |
| Arrhythmia | 1 | 0 | 1.00 |
| Pulmonary TB | 2 | 2 | 0.616 |
| Previous abdominal surgery | 0 | 1 | 0.360 |
| ASA score | |||
| 1 | 2 | 0 | 0.561 |
| 2 | 41 | 24 | |
| 3 | 5 | 3 | |
| Causes of cirrhosis | |||
| HBV | 29 | 11 | 0.044 |
| HCV | 5 | 0 | |
| Alcoholic | 7 | 9 | |
| Unknown | 7 | 7 | |
| Child-Pugh class | |||
| A | 43 | 24 | 1.00 |
| B | 5 | 3 | |
OG open gastrectomy group, LG laparoscopic or laparoscopic-assisted gastrectomy group, ASA American Society of Anesthesiologists
Pre- and postoperative day 1, 3 and 6 laboratory tests
| Preop laboratory test | OG (48) | LG (27) |
|
|---|---|---|---|
| Albumin (g/dl) | 3.8 ± 0.6 | 3.7 ± 0.5 | 0.571 |
| AST (IU/l) | 45.5 ± 52.7 | 32.1 ± 13.8 | 0.100 |
| ALT (IU/l) | 34.7 ± 31.1 | 29.3 ± 18.4 | 0.408 |
| Alkaline phosphatase (IU/l) | 75.3 ± 23.9 | 90.7 ± 45.3 | 0.060 |
| Total bilirubin (mg/dl) | 0.9 ± 0.3 | 0.9 ± 0.3 | 0.852 |
| Prothrombin time (INR) | 1.1 ± 0.2 | 1.1 ± 0.1 | 0.603 |
| Prothrombin time (%) | 88.6 ± 17.6 | 89.1 ± 15.5 | 0.912 |
| AFP (ng/ml) | 21.9 ± 53.3 | 6.8 ± 9.0 | 0.437 |
| CEA (ng/ml) | 1.7 ± 1.2 | 2.2 ± 1.4 | 0.166 |
| CA19-9 (U/ml) | 17.9 ± 28.4 | 10.3 ± 9.3 | 0.260 |
| POD#1 laboratory tests | |||
| Albumin (g/dl) | 3.0 ± 0.4 | 3.0 ± 0.3 | 0.821 |
| AST (IU/l) | 62.9 ± 77.0 | 61.0 ± 46.1 | 0.907 |
| ALT (IU/l) | 47.9 ± 61.4 | 54.9 ± 44.8 | 0.610 |
| Alkaline phosphatase (IU/l) | 59.0 ± 19.2 | 89.8 ± 117.6 | 0.189 |
| Total bilirubin (mg/dl) | 1.3 ± 0.5 | 1.3 ± 0.6 | 0.595 |
| Prothrombin time (INR) | 1.24 ± 0.3 | 1.26 ± 0.04 | 0.796 |
| Drain amount (ml) | 240 ± 305 | 220 ± 374 | 0.827 |
| POD#3 laboratory tests | |||
| Albumin (g/dl) | 3.0 ± 0.4 | 2.9 ± 0.4 | 0.811 |
| AST (IU/l) | 39.3 ± 28.9 | 28.1 ± 10.5 | 0.024 |
| ALT (IU/l) | 38.4 ± 39.7 | 31.4 ± 21.6 | 0.407 |
| Alkaline phosphatase (IU/l) | 54.8 ± 14.4 | 58.1 ± 20.8 | 0.432 |
| Total bilirubin (mg/dl) | 1.3 ± 0.8 | 1.3 ± 0.7 | 0.726 |
| Prothrombin time (INR) | 1.25 ± 0.24 | 1.29 ± 0.03 | 0.613 |
| Drain amount (ml) | 341 ± 369 | 220 ± 338 | 0.200 |
| POD#6 laboratory tests | |||
| Albumin (g/dl) | 3.1 ± 0.4 | 3.0 ± 0.3 | 0.641 |
| AST (IU/l) | 33.7 ± 12.6 | 28.5 ± 6.3 | 0.033 |
| ALT (IU/l) | 38.5 ± 34.5 | 22.6 ± 13.9 | 0.040 |
| Alkaline phosphatase (IU/l) | 65.4 ± 19.8 | 68.8 ± 29.8 | 0.606 |
| Total bilirubin (mg/dl) | 1.4 ± 1.5 | 1.2 ± 0.5 | 0.471 |
| Prothrombin time (INR) | 1.27 ± 0.28 | 1.23 ± 0.18 | 0.762 |
| Drain amount (ml) | 310 ± 352 | 173 ± 254 | 0.182 |
OG open gastrectomy group, LG laparoscopic or laparoscopic-assisted gastrectomy group, POD# postoperative day number
Operative details
| OG (48) | LG (27) |
| |
|---|---|---|---|
| Extent of LN dissectiona | |||
| D0 | 17 | 2 | 0.002 |
| D1 | 8 | 3 | |
| D1+ | 14 | 6 | |
| D2 | 9 | 16 | |
| TNM stage | |||
| Ia | 44 | 25 | 0.741 |
| Ib | 3 | 2 | |
| IIa | 1 | 0 | |
| Reconstruction | |||
| GD | 35 | 22 | 0.656 |
| GJ | 6 | 1 | |
| GJJJ | 5 | 3 | |
| RYGJ | 2 | 1 | |
| Op time (min) | 134.4 ± 41.0 | 153.4 ± 47.9 | 0.076 |
| No. of retrieved LNs | 20.3 ± 9.7 | 30.6 ± 15.3 | 0.003 |
| Hospital stay (days) | 14.5 ± 6.2 | 11.2 ± 3.7 | 0.005 |
| Drain amount until POD#6 | 1851 ± 1772 | 1177 ± 1866 | 0.157 |
aAccording to the 2010 Japanese gastric cancer treatment guidelines (ver. 3) [6]
OG open gastrectomy group, LG laparoscopic or laparoscopic-assisted gastrectomy group, LN lymph node, GD gastrodeudenal anastomosis, GJ gastrojejunal anastomosis, GJJJ gastrojejunal with jejunojejunal anastomosis, RYGJ Roux-en-Y gastrojejunal anastomosis, POD# postoperative day number
Morbidity and mortality
| OG (48) | LG (27) |
| |
|---|---|---|---|
| Complications severitya | |||
| None | 39 (81.3%) | 23 (85.2%) | 0.464 |
| Grade I | 1 (2.1%) | 2 (7.4%) | |
| Grade II | 7 (14.6%) | 2 (7.4%) | |
| Grade V | 1 (2.1%) | 0 (0.0%) | |
| Morbidity | |||
| None | 39 | 23 | 0.514 |
| Pneumonia | 1 | 1 | |
| Wound | 1 | 2 | |
| Leakage | 1 | 0 | |
| Bleeding | 4 | 0 | |
| Others | 2 | 1 | |
| Transfusion | |||
| RBC | 3 | 0 | 0.549 |
| FFP | 1 | 0 | 1.000 |
| In-hospital mortality | 1 | 0 | 1.000 |
OG open gastrectomy group, LG laparoscopic or laparoscopic-assisted gastrectomy group
aThe Clavien-Dindo classification of surgical complications. Grade I: any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic or radiological interventions. Allowed therapeutic regimens are: drugs as antiemetics, antipyretics, analgesics, diuretics and electrolytes and physiotherapy, including wound infections opened at the bedside. Grade II: requiring pharmacological treatment with drugs other than those allowed for grade I complications. Blood transfusions and total parenteral nutrition are also included. Grade IIIa: requiring surgical, endoscopic or radiological intervention not under general anesthesia; grade IIIb: an intervention under general anesthesia. Grade IVa: a life-threatening complication (including CNS complications) + requiring IC/ICU management with single-organ dysfunction (including dialysis); grade IVb: multiorgan failure. Grade V: death of the patient
Fig. 1Long-term survival. a Recurrence-free survival; b overall survival
Long-term recurrence and death
| OG (48) | LG (27) |
| |
|---|---|---|---|
| Mean follow-up period (month) | 55.5 ± 35.9 | 46.8 ± 27.8 | 0.248 |
| Recurrence | 2 | 1 | 1.000 |
| Cause of death | 0.313 | ||
| Gastric cancer | 2 | 0 | |
| Liver | 4 | 1 | |
| Other cause | 2 | 1 |
OG open gastrectomy group, LG laparoscopic or laparoscopic-assisted gastrectomy group